RxDoctor Payments Data

Nilah Bonham

Optometrist · Brazil, INNPI 1275635534

Payments from drug & device makers

$2,311in general payments, 2019–2025

Across 77 payments — averaging $30.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$398
  • Bausch & Lomb Americas Inc.$369
  • Alcon$210
  • LKC Technologies, Inc.$195
  • Novartis$175
  • Kala Pharmaceuticals, Inc.$129
  • plus $837 from 12 others
$360in research payments, 2019–2025

Across 8 payments — averaging $45.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Notal Vision, Inc.$360

What the payments were for

  • Food & beverage$2,17599%
  • Entertainment$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,311 in reported general payments places this provider in the 80th percentile of 1,318 optometrist providers in Indiana.

See all optometrist providers in Indiana

Medicare billing

Part B allowed, 2024
$76,593
Medicare patients
607
Services billed
1,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine36$51,120
LumiganBimatoprost16$12,928
MieboPerfluorohexyloctane/Pf13$10,018
Cyclosporine17$4,005
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$2,905
Latanoprost174$2,010
Brimonidine Tartrate52$627
Prednisolone Acetate21$590
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat37$351
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha35$339
Timolol Maleate20$185
Cephalexin14$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$398$64,04752 claims
Bausch & Lomb Americas Inc.Miebo$369$10,01813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,318 optometrist providers in Indiana.

Other optometrist in Brazil

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →